Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Retinoids kill childhood brain tumor cells

06.08.2003


Previous Food and Drug Administration approval for use of retinoids to treat another form of childhood cancer, will mean clinical trials in pediatric medulloblastoma patients to begin with minimal delay



Researchers find that vitamin A derivatives may be highly effective and minimally toxic treatments for medulloblastoma, the most common form of childhood brain cancer. Clinical trials of the drugs, known as retinoids, are being planned for children who are at high risk for tumor relapse following standard therapy.

A study led by Fred Hutchinson researchers, Drs. Andrew Hallahan and James Olson showed that retinoids killed cancer cells from medulloblastoma tumors that had been surgically removed from patients as well as tumors that had been grafted onto mice. Through genome analysis, the scientists also identified a protein in medulloblastoma cells that is triggered by retinoids to initiate cell death, a finding that is likely to lead to the development of additional therapies for the disease. The study appears in the Aug. 3 issue of Nature Medicine.


Because retinoids already have received approval from the Food and Drug Administration for treatment of another childhood cancer, neuroblastoma, researchers expect that the drugs will enter clinical trials in pediatric medulloblastoma patients with minimal delay.

Medulloblastomas arise from primitive cells in the back of the brain, or cerebellum, a region important for motor control and spatial orientation. The disease primarily strikes children under the age of 7. Standard therapy, which includes surgical removal of the tumor followed by radiation and a year of chemotherapy, offers about a 70 percent chance of survival for children over age 3 who do not have recurrent cancer.

High-risk children, who include those under age 3 or who have recurrent disease, have a much lower chance of survival with standard therapy. For that reason-and because of the toxic side effects of radiation and chemotherapy in young children-scientists are eager to find new treatments.

According to Hallahan, retinoids could prove to be even more effective at treating medulloblastoma than neuroblastoma.

"These compounds work against neuroblastoma and other cancers because they trigger cells to differentiate (form specialized cells) and stop dividing," he said. "But we observed that when the compounds are applied to medulloblastoma tumors, a large percentage of cancer cells actually die."

Retinoids are molecules naturally produced by the human body, where they play a critical role in normal development by triggering primitive cells to become specialized cells characteristic of a particular tissue, such as nerve cells in the brain. Scientists also have created synthetic retinoids, which have proved to be effective against some tumors because they drive cancer cells from their relatively primitive, undifferentiated state into specialized cells that cease to divide.

Hallahan and colleagues examined the effect of three retinoids on medulloblastoma tumor specimens obtained from surgeries.

"Thanks to our colleagues at Children’s Hospital and Regional Medical Center in Seattle we were able to start our experiments right in the operating room by getting surgical sections that we could immediately put into culture medium," James Olson said. "This was a critical step because it was uncertain whether the available medulloblastoma cell lines (cells previously extracted from tumors and grown indefinitely in the laboratory) would accurately reflect the disease."

The experiment led to a surprising result, Hallahan said. "We began by looking for signs of differentiation, which is what we expected based on how the compounds affect neuroblastomas," he said. "About 5 to 10 percent of the medulloblastoma cells did differentiate. But what was immediately obvious to us was that there was a huge wave of cell death."

The researchers also found that mice transplanted with medulloblastoma tumors that were treated with retinoids developed tumors that were about a third of the size as those that grew on untreated mice.

To identify genes responsible for the cell death, researchers looked at patterns of gene expression in medulloblastoma cells that were exposed to retinoids compared to untreated cells. Using DNA microarrays, which permit the analysis of thousands of genes simultaneously, they identified common sets of genes that were turned on or off in response to treatment with each of the three compounds.

Among the genes found to be switched on by retinoids was BMP-2 (bone morphogenetic protein-2), which codes for a protein thought to play a role in cell death and in the development of nervous system tissue that gives rise to medulloblastomas.

The addition of purified BMP-2 protein to medulloblastoma cells caused significant cell death, even to cells that were resistant to retinoids. Further, when retinoid-senstive cells were grown in close proximity to resistant cells, both types of cells were killed after addition of retinoids. This result indicates that BMP-2 protein secreted by the sensitive cells triggers killing of the neighboring drug-resistant cells.

"This has significant clinical implications," Hallahan said. "Tumors contain mixture of cell types, some of which may be resistant to certain drugs. Our results suggest that retinoid treatment could still manage to kill resistant cells that are in proximity to drug-responsive cells in the tumor."

Olson said that it also suggests that BMP-2 or other proteins "downstream" in the retinoid-induced cell-death cascade could be potential targets for new anticancer drugs.

A proposed clinical trial for high-risk pediatric medulloblastoma patients to compare standard therapy plus retinoids to standard therapy alone is now under review by the Children’s Oncology Group, a National Cancer Institute-supported clinical trials cooperative group whose member institutions are devoted exclusively to childhood and adolescent cancer research. Olson, who will serve as principal investigator of the study, hopes to begin the trial at 235 hospitals sometime within the next year.

"It’s tremendously satisfying to see a new therapy move so quickly through the pipeline," he said. "One major reason this has progressed so rapidly is that retinoids already have been approved for use in childhood cancers. But equally important has been the center’s unique research environment-with strengths in laboratory science and pediatric oncology-combined with the opportunity for collaboration with physician’s at Children’s, which allowed us to take this study all the way from basic genetics to propose a clinical trial," Olson said.

Susan Edmonds | EurekAlert!
Further information:
http://www.fhcrc.org

More articles from Studies and Analyses:

nachricht Antarctic Ice Sheet mass loss has increased
14.06.2018 | Technische Universität Dresden

nachricht WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>